Navigation Links
Dry Eye Survey: Ophthalmologists Cite Treatment Limitations/Gaps in Treatment of Moderate to Severe Dry Eye
Date:11/10/2008

LAWRENCEVILLE, N.J., Nov. 10 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, announced results of a recent survey of ophthalmologists regarding issues in the treatment of moderate to severe cases of dry eye. Aton provides the dry eye medication Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert), a preservative-free, once-daily*, sustained release prescription insert that helps to retain moisture, stabilize the tear film, and lubricate the eye.

Nearly all of the ophthalmologists surveyed (94%) believe more treatment options are needed for moderate to severe dry eye. While 80% feel current therapies are effective for mild dry eye, only 33% feel they are effective for moderate dry eye and 67% feel they are only somewhat effective or not very effective. Only 5% feel current therapies are effective for severe dry eye, while 56% feel they are somewhat effective and 38%, not very or not at all effective.

"Ophthalmologists are still looking for more effective therapies for treating moderate to severe dry eye," commented Dr. Penny Asbell, Professor, Department of Ophthalmology, Mount Sinai School of Medicine; Director, Cornea Services and Refractive Surgery Center, New York; and co-author of the pivotal textbook 'Dry Eye Disease, the Clinician's Guide to Diagnosis and Treatment.' "Nearly all ophthalmologists want more treatment options for these more serious cases." Dr. Asbell is a member of Aton Pharma's Scientific Advisory Board.

"We are proud to be working with Dr. Asbell to contribute to eye care professionals' insights about the state of the art of treatment of dry eye," stated Michael G. Wells, Chief Executive Officer of Aton Pharma. "Ophthalmology is one of the important markets Aton serves as a diversified specialty pharmaceutical company providing medically essential therapies to patients around the world."

Treatment Approaches and Options

The survey respondents reported that over the
'/>"/>

SOURCE Aton Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Survey: 90% of Participating Surgeons Report Syndicom SpineConnect Improves Practice of Spine Surgery
2. AstraZeneca Survey: Healthcare Professionals Leading Source of Information on Companys Prescription Savings Programs
3. Wedgewood Pharmacy Will Continue to Provide Avastin(R) to Ophthalmologists and Retinal Specialists
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
8. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
9. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
10. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
11. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... The two humanitarian organi... programs, including biomedical repair technologie...fit the West African country of Togo. , ... -- With the recent signing of a Memorandum of Und... have formalized a partnership to help develop sus...
(Date:11/30/2009)... , COLUMBUS, Ohio, Nov. 30 ...t for one of the nation,s first minority business ...d in Cleveland December 3, is called "Transforming...Business Early-Stage Capital Summit." It will feat... minority business leaders and local minority entr...
(Date:11/30/2009)... , NEW YORK, Nov. 30 /PRNewswire-USNewswire... Research (MJFF) today announced $1.5 million in t...op potentially disease-modifying therapies for Par...e Novel Approaches to Drug Discovery for Parkinso...m Elan Corporation, plc (NYSE: ELN ), a neurosci...
(Date:11/30/2009)... , CHICAGO, Nov. 30 Dr. Jessi...eorge Washington University Medical Center in Wash... of Breast-Specific Gamma Imaging (BSGI) in clinic... diagnosis of breast cancer today at the annual me... (RSNA). ,, "The purpose of the exhibit was to ...
Breaking Biology Technology:Mercy Ships and MediSend International Partner to Deliver Hope and Healing 2Mercy Ships and MediSend International Partner to Deliver Hope and Healing 3Ohio Capital Fund Announces Sponsorship of Minority Business Conference 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3Breast-Specific Gamma Imaging In Clinical Practice as an Adjunct Imaging Modality for Diagnosis of Breast Cancer 2
...Calif., Dec. 28 Beckman Coulter,Inc. (NYSE: BEC ... of,products that simplify, automate, and innovate...cott Garrett, Beckman Coulter,s president and chie...Healthcare Conference on,Tuesday, January 8, 2008,...om/cgi-bin/prnh/20031202/BECLOGO ), The live webc...
...Y, Calif., Dec. 28 Maxygen, Inc.,(Nasdaq: MAXY )...nt of,improved protein drugs, today announced that...hcare Conference on Monday, January 7, 2008 at,9:0...ef executive officer,and Santosh Vetticaden, Maxyg...ebcast of the presentation can be accessed on Maxy...
...nference Call Scheduled for December 28, 2007 at 8... PALO ALTO, Calif., Dec. 27 Alexza,Pharmaceutica...has initiated,a license and development partnershi... ENDP ) for AZ-003 (Staccato(R) fentanyl) and the...rrently in Phase 1 clinical,development, AZ-003 is...
Other Biology Technology:Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America 2Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America 3Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America 4Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America 5
(Date:12/1/2009)...nology has been awarded a U.S. Air Force Center of...rvesting and adaptive materials, and to develop to...e modern warfighter. , The $10.5 million Center...Nanostructures and Improved Cognition (BIONIC) cen...Sandhage, professors in Georgia Tech,s School of M...
(Date:12/1/2009)...ersity-led international research team has develop...xt generation of solar cells. , Scientists at Mo...from the universities of Wollongong and Ulm in Ger...lls with a three-fold increase in energy conversio...dem dye-sensitised solar cells. , Lead research...
(Date:11/30/2009)...s needed to monitor the commitments that will be m...heir deforestation rates, according to research at...agencies and research groups have failed to make f...e Earth,s surface collected each week to monitor t...r Alan Grainger in the Proceedings of the Nationa...
Breaking Biology News(10 mins):Air Force Center of Excellence awarded in nanostructures and improved cognition 2Air Force Center of Excellence awarded in nanostructures and improved cognition 3Air Force Center of Excellence awarded in nanostructures and improved cognition 4Innovation puts next-generation solar cells on the horizon 2World forest observatory needed to monitor vital role of forests in climate deal 2PHSI INC Develops Revolutionary Vision Hearing Program 60210 1PHSI INC Develops Revolutionary Vision Hearing Program 60210 2New York Merchants Protective Co Designated as Authorized Geutebruck Solutions Provider 60207 1New York Merchants Protective Co Designated as Authorized Geutebruck Solutions Provider 60207 2New York Merchants Protective Co Designated as Authorized Geutebruck Solutions Provider 60207 3UHC Benchmarking Project Focuses on Patient and Family Centered Care in Academic Medical Centers 60204 1UHC Benchmarking Project Focuses on Patient and Family Centered Care in Academic Medical Centers 60204 2UHC Benchmarking Project Focuses on Patient and Family Centered Care in Academic Medical Centers 60204 3
...reased in both the USA and the UK over the years a...ood body mass index (BMI). However, many of the re... have been flawed. A recent scientific analysis o...diets and lifestyles found no link between the amo... weight. , UK researchers, led by Sigrid Gibson ...
...tainly walked upright on two legs but may have str..., new research suggests. , The University of Manc...tion for the Advancement of Science) Festival of S...humans lacked an Achilles tendon, as modern chimps...have been severely compromised. , Our research su...
...tes can be understood using artificially-intellige... new research published in a special edition of Ph...d presented at the BA Festival of Science in York....e instructions to work out why some primate groups...turning previous theories developed by primatologi...
Other Biology News:Soft drinks alone do not affect children's weight 2Was ability to run early man's Achilles heel? 2Was ability to run early man's Achilles heel? 3Primate behavior explained by computer 'agents' 2
...erformance, 5 ml. The same high performance strept...or fast, reliable purification of biotinylated com...16/20, or other columns when larger scale purifica... either the strong interactions of biotin and stre...
Immunoprecipitation Starter Pack from GE Healthcare, formerly Amersham Biosciences
Prolong Gold Antifade Reagent from Invitrogen
GIBCO Modified Eagle Medium (MEM) (2X); liquid from Invitrogen
Biology Products: